
Researchers explore highly engaged social media posts related to glucagon-like peptide-1 receptor agonists, attention deficit/hyperactivity disorder stimulants, and autoimmune biologics.

Researchers explore highly engaged social media posts related to glucagon-like peptide-1 receptor agonists, attention deficit/hyperactivity disorder stimulants, and autoimmune biologics.

This episode explores ongoing developments in pharmacy law, specifically for independent pharmacies and their representatives who attended the 2025 NCPA Convention & Expo.

This collaboration is designed to bring resources addressing pharmacy shortages to the fingertips of the general public.

A study shows dupilumab significantly improves symptoms of allergic fungal rhinosinusitis, offering hope for effective treatment options.

The event will explore the importance of advocacy, gathering experts all across community pharmacy to discuss improving patient access and education.

With a new year approaching, pharmacy law experts joined Over the Counter to recap some of the key events regarding state- and federal-level PBM reform throughout 2025.

With evidence of antiobesity properties in human trials, berberine could be an OTC phytotherapeutic option for weight loss.

New findings reveal semaglutide 2.4 mg improves liver health in MASH patients, showing benefits beyond weight loss, as presented at The Liver Meeting 2025.

Investigators analyze COVID-19 positivity trends in NYC, revealing disparities among children and racial groups during the Omicron variant surge.

Steve Leonard, PharmD, BCIDP, joins Drug Topics on World Pneumonia Day to discuss pharmacists’ role in managing the disease.

Study findings highlight the need for further exploration into the racial and ethnic trends of pneumococcal vaccination rates.

To celebrate World Pneumonia Day, Steve Leonard, PharmD, BCIDP, joined us to discuss the variety in pneumonia types and available treatment options commonly prescribed.

Eloralintide shows promising weight loss results in a phase 2 trial, offering a new option for obesity management with improved tolerability.

In patients with diabetes and various levels of UACR, researchers aimed to uncover both the relative and absolute effects of SGLT2 inhibitors.

A study explored how SGLT2 inhibitors impact the kidney, specifically whether effects varied by estimated glomerular filtration rate (eGFR) or albuminuria.

A secondary analysis of the Obesity-Fertility lifestyle intervention program explored how it impacted the behavior of women with obesity and subfertility.

The NCPDP gathered essential members from the pharmacy community in a roundtable discussion on electronic prior authorizations.

This episode explores the complex composition of a good leader within the pharmacy industry.

Living in the state of West Virginia for over a decade, Mark Garofoli, PharmD, BCGP, CPE, CTTS, shares his experience as a practicing pharmacist amid the US opioid crisis.

Oral semaglutide 25 mg shows significant benefits in weight loss and cardiovascular health for patients with obesity, enhancing overall well-being.

Mark Garofoli, PharmD, BCGP, CPE, CTTS, shares his pain management expertise and discusses current developments in the US opioid epidemic.

Researchers investigate women’s experiences in accessing either prescription or OTC contraceptives.

Finerenone shows promise in reducing kidney damage for type 1 diabetes patients, marking a significant advancement in chronic kidney disease treatment.

To optimize vaccine strategies among young people with Down syndrome, researchers explore the prevalence of adequate immune responses following pneumococcal vaccination.

Through diabetes education and initiatives focused on community health care, Clipper F. Young, PharmD, MPH, CDCES, BC-ADM, BCGP, is making a difference for patients and the pharmacy profession.

Older adults with dementia face significantly higher COVID-19 risks, highlighting the need for targeted health strategies during pandemics.

FDA approves lumateperone as an adjunct therapy for major depressive disorder, offering new treatment options for this indication.

A study reveals tailored glucose monitoring intervals for type 2 diabetes patients based on HbA1c levels, enhancing long-term management strategies.

Episode 4 of Wicked Good Cardiometabolic Chat explores SGLT2 inhibitors and their efficacy beyond diabetes outcomes alone.

Experts discuss the implications of the Most Favored Nation drug policy, discussing its impact on pricing, community pharmacy, and patient safety in the final part of a webinar series.